What is Sidoti Csr's Estimate for USNA FY2025 Earnings?

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Sidoti Csr increased their FY2025 earnings per share estimates for shares of USANA Health Sciences in a research report issued on Wednesday, April 23rd. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will post earnings per share of $2.61 for the year, up from their previous estimate of $2.59. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences' Q4 2025 earnings at $0.68 EPS, Q2 2026 earnings at $0.79 EPS and Q4 2026 earnings at $0.93 EPS.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.70 by $0.03. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The firm had revenue of $249.54 million during the quarter, compared to analyst estimates of $243.08 million. During the same period last year, the company posted $0.86 EPS.

Several other research analysts have also weighed in on USNA. DA Davidson lowered their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, February 27th. StockNews.com downgraded USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. Finally, Sidoti downgraded USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th.

USANA Health Sciences Stock Performance

Shares of USNA stock traded up $0.29 during mid-day trading on Friday, hitting $27.47. The company's stock had a trading volume of 223,722 shares, compared to its average volume of 122,763. The company's fifty day simple moving average is $27.78 and its 200-day simple moving average is $33.12. USANA Health Sciences has a 52 week low of $23.10 and a 52 week high of $49.78. The company has a market cap of $518.08 million, a PE ratio of 9.71, a P/E/G ratio of 0.93 and a beta of 1.00.

Insider Activity

In related news, CEO Jim Brown sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the sale, the chief executive officer now directly owns 15,716 shares of the company's stock, valued at approximately $463,150.52. This represents a 24.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David Mulham Mulham sold 3,234 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the completion of the sale, the insider now directly owns 12,775 shares of the company's stock, valued at $421,319.50. The trade was a 20.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,920 shares of company stock worth $500,285 in the last three months. Company insiders own 0.63% of the company's stock.

Institutional Investors Weigh In On USANA Health Sciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC raised its position in USANA Health Sciences by 111.9% in the 3rd quarter. Barclays PLC now owns 27,737 shares of the company's stock valued at $1,052,000 after buying an additional 14,647 shares during the last quarter. Pzena Investment Management LLC increased its position in shares of USANA Health Sciences by 3.6% during the 4th quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock valued at $39,015,000 after purchasing an additional 37,466 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of USANA Health Sciences by 2.8% during the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company's stock valued at $1,924,000 after purchasing an additional 1,480 shares during the last quarter. Rhumbline Advisers increased its position in shares of USANA Health Sciences by 39.8% during the 4th quarter. Rhumbline Advisers now owns 49,390 shares of the company's stock valued at $1,773,000 after purchasing an additional 14,068 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of USANA Health Sciences during the 4th quarter valued at $953,000. 54.25% of the stock is owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.